Spectrophotometric analysis of amniotic fluid in Rhsensitized pregnant women has produced a dramatic change in the management of these patients while improving the outlook for the fetus.1 This test represents a significant addition to medical horizons because it offers a biochemical quantitation of fetal substances as the basis for venturing into intrauterine fetal therapy. This report represents a consolidation of two experiences in two separate centers and identifies diagnostic features which are the basis of current management.
In a previous report the spectrophotometric analysis of amniotic fluid was described and the available information relating to the test was summarized.2 During the past year there have been many additional reports confirming the value of this procedure.1,3-6 One of the unfortunate developments in reporting the data is the lack of uniformity.1-3 We have tried to analyze the basis for the diverse kinds of data-reporting different from
Schulman H, Mann L, Hayashi TT. The Rh-Sensitized Pregnant Woman. JAMA. 1966;196(2):171–172. doi:10.1001/jama.1966.03100150117029
Customize your JAMA Network experience by selecting one or more topics from the list below.